211 Rn/ 211 At and 209 At production with intense mass separated Fr ion beams for preclinical 211 At-based α-therapy research.

Autor: Crawford JR; TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada; Department of Physics and Astronomy, University of Victoria, 3800 Finnerty Road, Victoria, British Columbia, V8P 5C2, Canada., Kunz P; TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada., Yang H; TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada., Schaffer P; TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada., Ruth TJ; TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada; Department of Physics and Astronomy, University of Victoria, 3800 Finnerty Road, Victoria, British Columbia, V8P 5C2, Canada.
Jazyk: angličtina
Zdroj: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine [Appl Radiat Isot] 2017 Apr; Vol. 122, pp. 222-228. Date of Electronic Publication: 2017 Jan 27.
DOI: 10.1016/j.apradiso.2017.01.035
Abstrakt: Mass-separated francium beams ( 211 Fr or 213 Fr) were implanted into solid targets for producing 211 Rn (14.6h half-life) or 209 At (5.41h), in situ. 211 Rn was transferred to dodecane and isolated from contaminants, providing sources for 211 At (7.21h) production by 211 Rn decay (73%). 209 At was recovered with high radionuclidic purity in aqueous solutions, directly. These experiments demonstrated Fr beam implantations as a novel method for producing preclinical quantities of 211 Rn/ 211 At (for therapy) and 209 At (for imaging).
(Copyright © 2017 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: